These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19648218)

  • 1. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central nervous system effects of haloperidol on THC in healthy male volunteers.
    Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
    Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
    J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
    de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
    J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intrapulmonary tetrahydrocannabinol administration in humans.
    Zuurman L; Roy C; Schoemaker RC; Hazekamp A; den Hartigh J; Bender JC; Verpoorte R; Pinquier JL; Cohen AF; van Gerven JM
    J Psychopharmacol; 2008 Sep; 22(7):707-16. PubMed ID: 18515447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
    Barbanoj MJ; García-Gea C; Antonijoan R; Izquierdo I; Donado E; Pérez I; Solans A; Jané F
    Hum Psychopharmacol; 2006 Jan; 21(1):13-26. PubMed ID: 16389668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.
    te Beek ET; Tatosian D; Majumdar A; Selverian D; Klaassen ES; Petty KJ; Gargano C; van Dyck K; McCrea J; Murphy G; van Gerven JM
    J Clin Pharmacol; 2013 Aug; 53(8):846-56. PubMed ID: 23775877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
    Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
    Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
    Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls.
    Palmer C; Ellis KA; O'Neill BV; Croft RJ; Leung S; Oliver C; Wesnes KA; Nathan PJ
    Hum Psychopharmacol; 2008 Mar; 23(2):151-9. PubMed ID: 17972276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.
    te Beek ET; Zoethout RW; Bani MS; Andorn A; Iavarone L; Klaassen ES; Fina P; van Gerven JM
    J Psychopharmacol; 2012 Feb; 26(2):303-14. PubMed ID: 22219221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance.
    Scholtissen B; Verhey FR; Adam JJ; Weber W; Leentjens AF
    Clin Neuropharmacol; 2006; 29(5):276-85. PubMed ID: 16960473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.
    García-Gea C; Martínez-Colomer J; Antonijoan RM; Valiente R; Barbanoj MJ
    J Clin Psychopharmacol; 2008 Dec; 28(6):675-85. PubMed ID: 19011437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flunitrazepam-induced changes in neurophysiological, behavioural, and subjective measures used to assess sedation.
    Lucchesi LM; Pompéia S; Manzano GM; Kohn AF; Galduroz JC; Bueno OF; Tufik S
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):525-33. PubMed ID: 12691789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine.
    Fredrickson A; Snyder PJ; Cromer J; Thomas E; Lewis M; Maruff P
    Hum Psychopharmacol; 2008 Jul; 23(5):425-36. PubMed ID: 18421801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
    Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
    Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine H1-receptor blockade in humans affects psychomotor performance but not memory.
    van Ruitenbeek P; Vermeeren A; Riedel W
    J Psychopharmacol; 2008 Aug; 22(6):663-72. PubMed ID: 18208925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
    te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
    J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.